Anika Therapeutics Overview
Valuation check: ANIK's ROE is -1.66%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-1.66%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Anika Therapeutics (ANIK) currently reports a ROE of -1.66%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Anika Therapeutics's ROE history and peer comparisons.
Anika Therapeutics's ROE of -1.66% is lower than the Healthcare sector average of 20.86%. That is roughly 107.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Anika Therapeutics's current -1.66% should be judged against Healthcare norms (sector average: 20.86%) and against ANIK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -1.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Anika Therapeutics, and consider following ANIK for alerts when major investors trade the stock.
Anika Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -1.66% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANIK with unrelated industries.
